企業・製品関連ニュース

Many chromatographic purifications of chemically synthesized therapeutics are governed by a yield-purity trade-off due to the presence of product-related impurities. The impurities partially overlap with the peak at preparative load conditions. The trade-off means that high product purity can only be achieved at the cost of yield (and vice-versa) or a recycling strategy has to be implemented.

Twin-column continuous countercurrent chromatography (MCSGP process) simultaneously achieves high yield and purity through automatic internal recycling of impure side fractions. Thereby MCSGP avoids excessive peak fractionation, fraction analysis and re-chromatography. Consequently, in production scale, much fewer samples need to be analyzed by QC and release times are shortened, allowing faster project turnover. Peptide and oligonucleotide purifications are two cases where the MCSGP process has shown excellent results. Both product classes have been purified at preparative scale obtaining high yield without compromising target purity.

This webinar briefly introduces the MCSGP process concept and recent results of oligonucleotide and peptide purification by countercurrent chromatography, and presents the key economic aspects for scale-up.